Deals
Fresenius CEO Raises Prospect of Two IPOs and Dialysis Unit Sale
- Company signals it’s open to sell stakes in Helios, Vamed
- Fresenius seeks new growth avenues to rebound from pandemic
This article is for subscribers only.
Fresenius SE is considering initial public offerings for two of its four business units and is open to fielding offers for its controlling stake in the already publicly traded kidney-dialysis division.
Fresenius is open to either an IPO or bringing on equity partners for its Helios division, which owns hospitals in Germany, Spain and Latin America, along with its Vamed unit that manages the construction and operation of healthcare centers, Chief Executive Officer Stephan Sturm said in a press conference Tuesday.